Ovid Therapeutics Inc. financial data

Symbol
OVID on Nasdaq
Industry
Pharmaceutical Preparations
Location
441 Ninth Avenue, 14 Th Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 758 % -44.6%
Debt-to-equity 49.8 % +145%
Return On Equity -39.2 % +5.94%
Return On Assets -26.2 % +24.5%
Operating Margin -11K % +38.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71M shares +0.47%
Common Stock, Shares, Outstanding 71M shares +0.47%
Entity Public Float 191M USD +53%
Common Stock, Value, Issued 71K USD +0.45%
Weighted Average Number of Shares Outstanding, Basic 71M shares +0.51%
Weighted Average Number of Shares Outstanding, Diluted 71M shares +0.51%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 632K USD +113%
Research and Development Expense 41.5M USD +76.5%
General and Administrative Expense 28.5M USD -5.18%
Operating Income (Loss) -69.3M USD -30.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -32.5M USD +33.1%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -32.5M USD +33%
Earnings Per Share, Basic -0.46 USD/shares +33.3%
Earnings Per Share, Diluted -0.46 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15M USD -73.9%
Cash, Cash Equivalents, and Short-term Investments 62.7M USD -28%
Assets, Current 65.8M USD -28.2%
Property, Plant and Equipment, Net 509K USD -40.6%
Operating Lease, Right-of-Use Asset 13.1M USD -7.6%
Other Assets, Noncurrent 182K USD -26.8%
Assets 103M USD -17.9%
Accounts Payable, Current 2.71M USD +123%
Employee-related Liabilities, Current 4.31M USD +12.2%
Accrued Liabilities, Current 7.61M USD +22.3%
Liabilities, Current 11.6M USD +34.2%
Operating Lease, Liability, Noncurrent 13.8M USD -8.7%
Liabilities 26.4M USD +11.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 36K USD
Retained Earnings (Accumulated Deficit) -295M USD -12.4%
Stockholders' Equity Attributable to Parent 76.3M USD -24.7%
Liabilities and Equity 103M USD -17.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.7M USD -37.8%
Net Cash Provided by (Used in) Financing Activities 228K USD +240%
Net Cash Provided by (Used in) Investing Activities 20.2M USD -33.2%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 71M shares +0.47%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.9M USD -71.5%
Deferred Tax Assets, Valuation Allowance 92.6M USD +25.7%
Deferred Tax Assets, Gross 92.6M USD +25.7%
Depreciation 412K USD -8.27%
Payments to Acquire Property, Plant, and Equipment 19K USD +35.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -32.5M USD +32.9%
Lessee, Operating Lease, Liability, to be Paid 19.9M USD -10.4%
Operating Lease, Liability, Current 1.31M USD +7.23%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.32M USD -0.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.32M USD -0.01%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.32M USD -0.01%
Deferred Tax Assets, Operating Loss Carryforwards 55.7M USD +0.33%
Preferred Stock, Shares Issued 1.25K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.47M USD +6.59%
Additional Paid in Capital 371M USD +2.05%
Preferred Stock, Shares Outstanding 1.25K shares 0%
Amortization of Intangible Assets 184K USD -0.58%
Depreciation, Depletion and Amortization 136K USD -6.21%
Share-based Payment Arrangement, Expense 6.81M USD -5.79%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%